{"ModuleTitle": "Company Description", "CompanyName": "Adamis Pharmaceuticals Corporation", "Symbol": "ADMP", "Address": "11682 EL CAMINO REAL SUITE 300, SAN DIEGO, California, 92130, United States of America", "Phone": "(858) 997-2400", "Industry": "Major Pharmaceuticals", "Sector": "Health Care", "Region": "North America", "CompanyDescription": "Adamis Pharmaceuticals Corporation (\"we,\" \"us,\" \"our,\" \"Adamis\" or the\r\n\"company\") is a specialty biopharmaceutical company focused on developing and\r\ncommercializing products in various therapeutic areas, including respiratory\r\ndisease, allergy and opioid overdose. Our products and product candidates in the\r\nallergy, respiratory, and opioid overdose markets include:  SYMJEPI(TM)\r\n(epinephrine) Injection 0.3mg, which was approved by the U.S.&nbsp;&nbsp;... <a href=\"http://secfilings.nasdaq.com/edgar_conv_html%2f2020%2f03%2f30%2f0001387131-20-003438.html#FIS_BUSINESS\" target=\"_blank\">More</a> ...&nbsp;&nbsp;\r\n", "KeyExecutives": [{"name": "David J. Marguglio", "title": "Director, Chief Business Officer & Senior VP"}, {"name": "Dennis J. Carlo", "title": "President, Chief Executive Officer & Director"}, {"name": "Karen K. Daniels", "title": "Vice President-Operations"}, {"name": "Robert O. Hopkins", "title": "Chief Financial Officer, Secretary & VP-Finance"}, {"name": "Ronald B. Moss", "title": "Chief Medical Officer"}], "Number_of_employees": ["NO INFO"], "Subsidiaries": ["NO INFO"]}